首页> 外文期刊>The Open Respiratory Medicine Journal >Inhalational Steroids and Iatrogenic Cushing’s Syndrome
【24h】

Inhalational Steroids and Iatrogenic Cushing’s Syndrome

机译:吸入类固醇与医源性库欣综合征

获取原文
       

摘要

Bronchial asthma (BA) and Allergic rhinitis (AR) are common clinical problems encountered in day to day practice, where inhalational corticosteroids (ICS) or intranasal steroids (INS) are the mainstay of treatment. Iatrogenic Cushing syndrome (CS) is a well known complication of systemic steroid administration. ICS /INS were earlier thought to be safe, but now more and more number of case reports of Iatrogenic Cushing syndrome have been reported, especially in those who are taking cytochrome P450 (CYP 450) inhibitors. Comparing to the classical clinical features of spontaneous Cushing syndrome, iatrogenic Cushing syndrome is more commonly associated with osteoporosis, increase in intra-ocular pressure, benign intracranial hypertension, aseptic necrosis of femoral head and pancreatitis, where as hypertension, hirsuitisum and menstrual irregularities are less common. Endocrine work up shows low serum cortisol level with evidence of HPA (hypothalamo-pituitary-adrenal) axis suppression. In all patients with features of Cushing syndrome with evidence of adrenal suppression always suspect iatrogenic CS. Since concomitant administration of cytochrome P450 inhibitors in patients on ICS/INS can precipitate iatrogenic CS, avoidance of CYP450 inhibitors, its dose reduction or substitution of ICS are the available options. Along with those, measures to prevent the precipitation of adrenal crisis has to be taken. An update on ICS-/INS- associated iatrogenic CS and its management is presented here.
机译:支气管哮喘(BA)和过敏性鼻炎(AR)是日常实践中遇到的常见临床问题,其中吸入性皮质类固醇(ICS)或鼻内类固醇(INS)是治疗的主要手段。医源性库欣综合征(CS)是全身性类固醇给药的众所周知的并发症。 ICS / INS以前被认为是安全的,但是现在已经报道了越来越多的医源性库欣综合征病例报告,特别是在那些服用细胞色素P450(CYP 450)抑制剂的患者中。与自发性库欣综合征的经典临床特征相比,医源性库欣综合征更常见于骨质疏松症,眼内压升高,颅内良性高血压,股骨头无菌性坏死和胰腺炎,而高血压,hirsuitisum和月经不调较少共同。内分泌检查显示血清皮质醇水平低,并伴有HPA(下丘脑-垂体-肾上腺)轴抑制的迹象。在所有具有库欣综合征特征且肾上腺抑制的证据的患者中,总是怀疑医源性CS。由于在ICS / INS上患者同时给予细胞色素P450抑制剂可引起医源性CS,因此避免CYP450抑制剂,降低其剂量或替代ICS是可行的选择。除了这些,还必须采取措施防止肾上腺危机的加剧。此处介绍了与ICS // INS相关的医源性CS及其管理的更新。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号